Effectiveness of long-acting risperidone in a patient with comorbid intellectual disability, catatonic schizophrenia, and oneiroid syndrome.

Abstract

A patient with comorbid intellectual disability, catatonic schizophrenia, and recurrent oneiroid state of consciousness improved on long-acting risperidone and remains well at the three-year follow-up. We report a case treated with 50 mg long-acting risperidone administered every 14 days, who has been followed-up for three years. We studied his regional cerebral blood flow through technetium-99 m hexamethylpropyleneamine oxime single-photon emission computed tomography after two years of treatment. Symptoms of catatonic schizophrenia improved after two months of treatment, followed suit by oneiroid syndrome remission. Two years later, his brain perfusion was normal. No side effect has occurred since the patient was started on long-acting risperidone. Long-acting risperidone proved to be safe and effective in treating symptoms of catatonia and oneiroid syndrome.

• Authors: Daniele Serata, Chiara Rapinesi, Georgios Demetrios Kotzalidis, Maria Chiara Alessi, Delfina Janiri, Anna Claudia Massolo, Vittoria Rachele Ferri, Silvia Criscuolo, Gemma Callovini, Gloria Angeletti, Paolo Girardi, Antonio Del Casale
• Journal: International journal of psychiatry in medicine (Int J Psychiatry Med) Vol. 50 Issue 3 Pg. 251-6 ( 2015) ISSN: 0091-2174 [Print] United States
• PMID: 26443711 (Publication Type: Case Reports, Journal Article)
• Copyright: © The Author(s) 2015.

Chemical References

• Antipsychotic Agents
• Ambroxol
• Risperidone

Topics

• Adult
• Ambroxol
• Antipsychotic Agents (pharmacokinetics, therapeutic use)
• Brain (diagnostic imaging, drug effects)
• Dreams (psychology)
• Follow-Up Studies
• Humans
• Intellectual Disability (complications, drug therapy)
• Male
• Radionuclide Imaging
• Risperidone (pharmacokinetics, therapeutic use)
• Schizophrenia, Catatonic (complications, drug therapy)
• Syndrome
• Treatment Outcome